Medical University of South Carolina (MUSC) is working to make treatment for depression more accessible with its new mobile ...

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.

Objective To determine the ability of transcranial magnetic stimulation (TMS) in detecting synaptic impairment in patients with Alzheimer’s disease (AD) and predicting cognitive decline since the ...

Nexstim Receives NBS System 5 Order from a University Hospital in Germany Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for ...